<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02610556</url>
  </required_header>
  <id_info>
    <org_study_id>2015-FXY-071-Dept. of RT</org_study_id>
    <nct_id>NCT02610556</nct_id>
  </id_info>
  <brief_title>Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma</brief_title>
  <official_title>Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With Intensity-modulated Radiotherapy in High Risk Locregionally Advanced Nasopharyngeal Carcinoma: a Phase 2 Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangdong Pharmaceutical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to evaluate the efficiency and toxicities of concurrent docetaxel and
      cisplatin with intensity-modulated radiotherapy in high risk locoregionally advanced
      nasopharyngeal carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients are randomly assigned to receive intensity-modulated radiotherapy (IMRT)
      with concurrent chemotherapy of docetaxel plus cisplatin or cisplatin alone. IMRT is
      delivered with a total dose of 68 Gy or higher in 33 fractions to the primary tumor.
      Concurrent chemotherapy in the experimental arm consists of docetaxel 60 mg/m², D1 and
      cisplatin 25 mg/m², D1-3 every 3 weeks for 3 cycles. Concurrent chemotherapy in the control
      arm consists of cisplatin 100 mg/m², D1 every 3 weeks for 3 cycles.The primary endpoint is
      overall survival (OS), defined as time from randomization to the day of death from any cause.
      Secondary end points include failure-free survival (FFS), locoregional relapse-free survival
      (LRFS), distant metastasis-free survival (DMFS) and the incidence of grade 3 or higher acute
      toxicities. All efficacy analyses are conducted in the intention-to-treat population, and the
      safety population include only patients who receive their randomly assigned treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>two year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>failure-free survival</measure>
    <time_frame>two year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant metastasis-free survival</measure>
    <time_frame>two year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>locoregional relapse-free survival</measure>
    <time_frame>two year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related acute adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>up to two months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>TP plus IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemotherapy: TP - Docetaxel 60mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DDP plus IMRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concurrent chemotherapy: DDP - Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin 2</intervention_name>
    <description>Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles</description>
    <arm_group_label>DDP plus IMRT</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 60 mg/m2, D1 every 3 weeks for 3 cycles</description>
    <arm_group_label>TP plus IMRT</arm_group_label>
    <other_name>T</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin 1</intervention_name>
    <description>Cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles</description>
    <arm_group_label>TP plus IMRT</arm_group_label>
    <other_name>P</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-modulated radiotherapy</intervention_name>
    <description>Intensity-modulated radiotherapy</description>
    <arm_group_label>TP plus IMRT</arm_group_label>
    <arm_group_label>DDP plus IMRT</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly histologically confirmed non-keratinizing (WHO 1991) nasopharyngeal carcinoma.

          -  Tumor staged as T1N3M0, T2-3N2-3M0 or T4N0-3M0 (the 2010 UICC/AJCC staging system).

          -  Pretreatment EBV DNA ≥ 1500 copies/mL.

          -  Karnofsky scale (KPS) ≥ 70.

          -  Adequate marrow: leucocyte count ≥ 4×10E9/L, hemoglobin ≥ 110g/L and platelet count ≥
             100×10E9/L.

          -  Normal liver function test: Alanine Aminotransferase (ALT), Aspartate Aminotransferase
             (AST) and bilirubin ≤ 1.5×upper limit of normal (ULN) concomitant with alkaline
             phosphatase (ALP) ≤ 2.5×ULN.

          -  Adequate renal function: creatinine clearance ≥ 60 ml/min or creatinine ≤ 1.5×ULN.

          -  Patients must give written informed consent.

        Exclusion Criteria:

          -  Prior malignancy, except adequately treated basal cell or squamous cell skin cancer,
             in situ cervical cancer.

          -  Pregnancy or lactation (consider pregnancy test in women of child-bearing age and
             emphasize effective contraception during the treatment period).

          -  History of previous radiotherapy (except for non-melanomatous skin cancers outside
             intended radiotherapy volume).

          -  Prior radiotherapy, chemotherapy or surgery (except diagnostic) to primary tumor or
             nodes.

          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the
             compliance of the trial, for example, unstable cardiac disease requiring treatment,
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose &gt;
             1.5×ULN), and emotional disturbance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fang-Yun Xie, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University Cancer Center,Guangzhou, Guangdong, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fang-Yun Xie, M.D.</last_name>
    <phone>+86-020-87342618</phone>
    <email>xiefy@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pu-Yun OuYang, M.D.</last_name>
    <phone>+86-020-87342618</phone>
    <email>ouyangpy@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fang-Yun Xie, M.D.</last_name>
      <phone>+86-020-87342618</phone>
      <email>xiefy@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Pu-Yun OuYang, M.D.</last_name>
      <phone>+86-020-87342618</phone>
      <email>ouyangpy@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang LN, Gao YH, Lan XW, Tang J, OuYang PY, Xie FY. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A large scale propensity-matched study. Oral Oncol. 2015 Oct;51(10):950-6. doi: 10.1016/j.oraloncology.2015.07.004. Epub 2015 Jul 21.</citation>
    <PMID>26209065</PMID>
  </reference>
  <reference>
    <citation>Xie FY, Zou GR, Hu WH, Qi SN, Peng M, Li JS. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma]. Ai Zheng. 2009 Mar;28(3):279-85. Chinese.</citation>
    <PMID>19619443</PMID>
  </reference>
  <reference>
    <citation>Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys. 1992;22(3):613-7.</citation>
    <PMID>1346533</PMID>
  </reference>
  <reference>
    <citation>Tishler RB, Geard CR, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 1992 Jun 15;52(12):3495-7.</citation>
    <PMID>1350755</PMID>
  </reference>
  <reference>
    <citation>Komatsu M, Shiono O, Taguchi T, Sakuma Y, Nishimura G, Sano D, Sakuma N, Yabuki K, Arai Y, Takahashi M, Isitoya J, Oridate N. Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck. Jpn J Clin Oncol. 2014 May;44(5):416-21. doi: 10.1093/jjco/hyu026. Epub 2014 Mar 30.</citation>
    <PMID>24688084</PMID>
  </reference>
  <reference>
    <citation>Inohara H, Takenaka Y, Yoshii T, Nakahara S, Yamamoto Y, Tomiyama Y, Seo Y, Isohashi F, Suzuki O, Yoshioka Y, Sumida I, Ogawa K. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):934-41. doi: 10.1016/j.ijrobp.2014.12.032.</citation>
    <PMID>25832686</PMID>
  </reference>
  <reference>
    <citation>Higuchi K, Komori S, Tanabe S, Katada C, Azuma M, Ishiyama H, Sasaki T, Ishido K, Katada N, Hayakawa K, Koizumi W; Kitasato Digestive Disease and Oncology Group. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):872-9. doi: 10.1016/j.ijrobp.2014.03.030. Epub 2014 May 24.</citation>
    <PMID>24867539</PMID>
  </reference>
  <reference>
    <citation>Chen X, Hong Y, Feng J, Ye J, Zheng P, Guan X, You X, Song H. Concurrent chemoradiotherapy comparison of taxanes and platinum versus 5-fluorouracil and platinum in nasopharyngeal carcinoma treatment. Chin Med J (Engl). 2014;127(1):142-9.</citation>
    <PMID>24384440</PMID>
  </reference>
  <reference>
    <citation>Baykara M, Buyukberber S, Ozturk B, Coskun U, Kaplan MA, Unsal DK, Dane F, Demirci U, Bora H, Benekli M; Anatolian Society of Medical Oncology. Efficacy and safety of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced nasopharyngeal cancers. Tumori. 2013 Jul-Aug;99(4):469-73. doi: 10.1700/1361.15096.</citation>
    <PMID>24326834</PMID>
  </reference>
  <reference>
    <citation>Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan AT, Huang PY, Benhamou E, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lu TX, Bourhis J, Pignon JP; MAC-NPC Collaborative Group. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015 Jun;16(6):645-55. doi: 10.1016/S1470-2045(15)70126-9. Epub 2015 May 6.</citation>
    <PMID>25957714</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Fang-Yun Xie</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>NPC</keyword>
  <keyword>concurrent chemotherapy</keyword>
  <keyword>docetaxel</keyword>
  <keyword>cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

